identification of unmet medical needs, relying on a high-level scientific advisory board and regular interactions with international Key Opinion Leaders to anchor its technological choices in concrete clinical challenges.

The company initially focused on developing intranasal solid dosage forms for chronic rhinosinusitis and chronic allergic rhinitis, before expanding its platform toward applications in central nervous system disorders, particularly schizophrenia. This trajectory led to the development of a proprietary intranasal solid-form platform, now positioned to address multiple respiratory and CNS indications.